[
    [
        {
            "time": "",
            "orginal_text": "控股东被申请破产:曾疯狂并购 誉衡药业断臂求生还有戏吗？ 减资破产",
            "features": {
                "keywords": [
                    "控股股东",
                    "破产",
                    "并购",
                    "誉衡药业"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "控股东被申请破产:曾疯狂并购 誉衡药业断臂求生还有戏吗？ 减资破产",
            "scores": {
                "News_content": "控股东被申请破产:曾疯狂并购 誉衡药业断臂求生还有戏吗？ 减资破产",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞医药获沪股通连续7日净买入累计净买入16.40亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "沪股通",
                    "净买入"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "恒瑞医药获沪股通连续7日净买入累计净买入16.40亿元",
            "scores": {
                "News_content": "恒瑞医药获沪股通连续7日净买入累计净买入16.40亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "20家药企，将接受现场检查",
            "features": {
                "keywords": [
                    "药企",
                    "现场检查"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "20家药企，将接受现场检查",
            "scores": {
                "News_content": "20家药企，将接受现场检查",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "恒瑞入局抗病毒领域，与国际巨头争抢百亿美元市场",
            "features": {
                "keywords": [
                    "恒瑞",
                    "抗病毒",
                    "国际市场"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "恒瑞入局抗病毒领域，与国际巨头争抢百亿美元市场",
            "scores": {
                "News_content": "恒瑞入局抗病毒领域，与国际巨头争抢百亿美元市场",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "中国股市：未来十年，是科技的时代！板块龙头、全球以及国内第一",
            "features": {
                "keywords": [
                    "中国股市",
                    "科技",
                    "板块龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中国股市：未来十年，是科技的时代！板块龙头、全球以及国内第一",
            "scores": {
                "News_content": "中国股市：未来十年，是科技的时代！板块龙头、全球以及国内第一",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "PD-1耐药性有望解决！TIM-3靶点获批临床，恒瑞、BMS、罗氏最新进展",
            "features": {
                "keywords": [
                    "PD-1",
                    "耐药性",
                    "TIM-3",
                    "恒瑞",
                    "BMS",
                    "罗氏"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "PD-1耐药性有望解决！TIM-3靶点获批临床，恒瑞、BMS、罗氏最新进展",
            "scores": {
                "News_content": "PD-1耐药性有望解决！TIM-3靶点获批临床，恒瑞、BMS、罗氏最新进展",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "高瓴火速再出手：这两家公司市值大涨170亿",
            "features": {
                "keywords": [
                    "高瓴",
                    "市值",
                    "大涨"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "高瓴火速再出手：这两家公司市值大涨170亿",
            "scores": {
                "News_content": "高瓴火速再出手：这两家公司市值大涨170亿",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "9日强势板块分析：软件医药股爆发 零售板块亮眼",
            "features": {
                "keywords": [
                    "软件",
                    "医药",
                    "零售",
                    "板块"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "软件",
                    "医药",
                    "零售"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "9日强势板块分析：软件医药股爆发 零售板块亮眼",
            "scores": {
                "News_content": "9日强势板块分析：软件医药股爆发 零售板块亮眼",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
            "features": {
                "keywords": [
                    "优先审评",
                    "重磅药物",
                    "达格列净片",
                    "维奈克拉片"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
            "scores": {
                "News_content": "被纳入优先审评的10款重磅药物 达格列净片、维奈克拉片",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "中信证券：药品研发国内巨头竞争优势明确 重点推荐恒瑞医药等",
            "features": {
                "keywords": [
                    "中信证券",
                    "药品研发",
                    "恒瑞医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "中信证券：药品研发国内巨头竞争优势明确 重点推荐恒瑞医药等",
            "scores": {
                "News_content": "中信证券：药品研发国内巨头竞争优势明确 重点推荐恒瑞医药等",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]